NCT06294301 - A Study of Single and Multiple Doses of LP-005 in Healthy Adult Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 19, 2023

Primary Completion Date

April 30, 2024

Study Completion Date

October 30, 2024

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

BIOLOGICAL

LP-005 Dose 1 (Single)

A single dose of LP-005 (Dose 1) was administered intravenously.

BIOLOGICAL

LP-005 Dose 2 (Single)

A single dose of LP-005 (Dose 2) was administered intravenously.

BIOLOGICAL

LP-005 Dose 3 (Single)

A single dose of LP-005 (Dose 3) was administered intravenously.

BIOLOGICAL

LP-005 Dose 4 (Single)

A single dose of LP-005 (Dose 4) was administered intravenously.

BIOLOGICAL

LP-005 Dose 5 (Single)

A single dose of LP-005 (Dose 5) was administered intravenously.

BIOLOGICAL

LP-005 Dose 6 (Single)

A single dose of LP-005 (Dose 6) was administered intravenously.

BIOLOGICAL

Placebo (Single)

A single dose of placebo was administered intravenously.

BIOLOGICAL

LP-005 Dose 7 (Multiple)

LP-005 (Dose 7) was administered multiple times intravenously.

BIOLOGICAL

LP-005 Dose 8 (Multiple)

LP-005 (Dose 8) was administered multiple times intravenously.

BIOLOGICAL

LP-005 Dose 9 (Multiple)

LP-005 (Dose 9) was administered multiple times intravenously.

BIOLOGICAL

Placebo (Multiple)

Placebo was administered multiple times intravenously.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Public Health Clinical Center, Shanghai